The present invention relates to a novel family of protein kinase inhibitors more specifically the present invention is directed to inhibitors of the Tec or Src protein kinase families. The present invention also relates to the processes of preparation of these compounds to pharmaceutical compositions comprising them and to their use in the treatment of proliferative inflammatory autoimmune or infectious diseases disorders or conditions in which protein kinase activity is implicated.